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From the B loche meal Laboratory and Neurological Clinic of the Psychoneurological Institute in Prus^kow-Warsaw, Poland
(Eingegangen am 10. April 1968)
The lipid pattern of blood serum has been studied in 32 patients with multiple sclerosis, in whom the disease was either remittent or
slowly progressive. Although total lipids, free and esterified cholesterol, a- and 0-lipoproteins and chylomicrons were found to be normal
in patients, minimal and maximal values showed wider ranges than in controls.
Cholesterol esters were slightly reduced (71,6 ± 31,7 mg/100 m/) in patients with clinical exacerbation as compared to patients with
"inactive" disease or healthy controls (160,4 ± 58,1 mg/100 m/).
Treatment with corticotrophin and hydrocortisone derivatives did not alter significantly any of the studied lipid constituents of the serum.
Bei 32 Patienten mit Multipler Sklerose (in Remission oder langsamer Progredienz) wurde das Lipidmuster im Serum untersucht. Ge-
samtlipide, freies und verestertes Cholesterin, a- und jS-Lipoproteine sowie die Chylomikronen waren bei diesen Patienten normal, Mini-
mal- und Maximalwerte zeigten eine größere Streuung als die Kontrollen. Bei Patienten mit klinischer Exacerbation waren, verglichen
mit Patienten mit „inaktiver" Erkrankung oder gesunden Kontrollpersonen (160,4 ± 58,1 mg/100 m/), die Cholesterinester leicht ver-
mindert (71,6± 31,7 mg/100 m/).
Keine der untersuchten Lipidfraktionen des Serums war bei Behandlung mit ACTH bzw. Hydrocortisonderivaten signifikant verändert.
An intensive neurochemical study of the brain and the
analysis of the lipid composition .of body fluids in
multiple sclerosis have shown lowered tissue concen-
tration of various lipids in demyelinating areas and
increased content of some of them in the cerebro-
spinal fluid (1—4). Within remission of the disease,
the serum level of total lipids, free and esterified chol-
esterol, lipoproteins, phospholipids and several fatty
acids was described as largely normal (5—8). However,
in exacerbations of the disease or after loading of
patients with fats some alterations in the lipid meta-
bolism were observed (9—12). On the grounds of
conflicting results in these studies and a lack of in-
formation on the effect of corticotrophin and hydro-
cortisone derivatives on serum lipids in multiple
sclerosis the present study was undertaken. The pur-
pose of this study was to compare the levels of serum
lipids in multiple sclerosis and healthy controls, as
well as to evaluate the effect of clinical exacerbation and
corticotrophin treatment on the lipid composition of the
blood serum in multiple sclerosis.
.Material and methods
The subjects of the present study comprised 32 patients with
multiple sclerosis. In all cases the diagnosis of multiple sclerosis
was made.after complete clinical examination and only virtually
certain cases were included in the study. The ages of patients
ranged from 16 to 63 years (mean age 33,2 years). The course of
the disease varied from 1 to 44 years. In 8 cases the estimations of
serum lipids were carried out within exacerbations. Fourteen
cases were found to be in remission and in 8 cases the estimations
were done during a slowly progressive stage of the disease.
Blood (10 m/) was drawn from each subject from the antecubital
vein after an overnight fast. The total serum lipids were estimated
according to the method of S WAHN (13). Cholesterol esters and
free cholesterol were determined using the chromatography
procedure described by KRAWCZYNSKI and coworkers (14).
Serum lipoproteins, chylomicrons and serum proteins were
analysed by paper electrophoresis according to the method of
BOGDANIKOWA (15).
Results.
In the first stage of this study a comparison was made
between the serum levels of total lipids, esterified and
free cholesterol, lipoproteins and chylomicrons from a
series of 32 patients with multiple sclerosis and in
healthy controls (Tab. 1).
Table 1 shows the mean values and the standard errors
of the means for different serum lipids. Statistical exam-
ination (STUDENT'S test) of the values obtained showed
that there was no significant difference between these
two groups. However, two facts were noteworthy:
In multiple sclerosis serum cholesterol esters did
show standard deviations of far wider range (± 63,5),
than did controls, and the percentage of chylomicrons
was slightly increased in this patient group (23,16%)
as compared with the control group (10,0%). These
results suggest greater fluctuations of cholesterol
esters and the tendency to increased concentration of
Ta*b. 1
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low density lipoproteins (chylomicrons) in the serum
of patients with multiple sclerosis.
In the second stage of the study the analysis of serum
lipids was performed according to the estimated ac-
tivity of the disease. The basal criteria on which the
grading was made were the following: subacute,
recent clinical deterioration (I group of patients with
exacerbation), lack of evidence of any clinical deterio-
ration (II group with stationary course) and slowly
deteriorating neurological disability (III group with
progressive course). The results of this analysis pre-
sents table 2.
There were no significant differences of the serum
lipids in any group, although a slightly lower con-
centration of cholesterol esters was found in patients
with clinical exacerbation. The number of patients
with subacute, active disease was small and therefore
these results are not completely convincing. In one of
the cases from the present series showing recent and
rapid deterioration, the concentration of serum free
and esterified cholesterol was diminished to 3 and
20 mg/100 ml respectively (normal means 49,0 and
121,9 mg/100 ml).
In the third part of this study another comparison was
made between the levels of serum lipids before and
after treatment with corticotrophin or hydrocortisone
derivatives. The results of this comparison are shown
in table 3.
As in previous comparisons the figures from table 3
show no statistical differences. Corticotrophin slightly
increased the content of total lipids (from 576 up to
696 mg/100 m/) and cholesterol esters (from 116 up to
133 mg/100 ml) and diminished the percentage of
serum y-globulins, but this influence did not reach
the level of statistical significance.
Discussion
After an overnight fast in multiple sclerotic subjects as
well as in healthy controls, serum chylomicrons were
identified only occasionally. Among 32 patients, chylo-
microns were not identified in 7 and in 25 these low
density lipoproteins were found to be in ranges between
16, 64 and 44, 49%. CSÖGÖR and coworkers (12)
stated that in multiple sclerosis, the serum concen-
tration of chylomicrons rose to greater extent after
loading with fats and persisted for a longer time than in
controls. According tö SKILLEN and coworkers (16)
the percentage of chylomicrons with a diameter ex-
ceeding 0,5 micron (S£ 104—105) did reach 55 in mul-
tiple sclerosis and was evidently higher than in controls
(34%). Although the present study showed normal
values of total serum lipids, mainly triglicerides bound
with lipoproteins, and of chylomicrons in multiple
sclerosis, there is a distinct possibility that in some
cases there is an increased alimentary lipemia. Because
of normal activity of lipoprotein lipase in multiple
sclerosis, as was shown by SCHÄR (17), it may be
supposed that in some conditions chylomicrons of
post-absorptive serum are assembled and metabolized
at a slower rate by hepatic cells than in healthy con-
trols.
Lipoprotein molecules are probably rapidly synthesized
de novo in the liver and their protein portion has a
short half life, (18). The a- and /Mipoproteins in fasting
serum were described in multiple sclerosis either as
normal, or the -fraction was found to be below normal
concentration (12, 19). In the post-absorptive state the
reduction of serum -lipoproteins and the elevation of
/J-lipoproteins in multiple sclerosis are the reverse
of that observed in healthy controls, where a-lipo-
proteins are probably involved in the lipid transport
Tab. 2
Serum lipid levels in remittent, slowly progressive and stationary multiple sclerosis*
Remittent form 8 cases Slowly progressive form 8 cases Stationary form 14 cases


























* All differences not significant
Tab. 3
Serum levels of lipids and proteins prior to and after treatment with corticotrophin or hydrocortisone derivatives in multiple sclerosis*
ACTH Group 18 cases
Before After
Hydrocortisone Group 5 cases
Before After


























































* Both groups before treatment versus groups after treatment: difference not significant
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from the intestinal mucosa to the liver. The Present
paper, however, does confirm the normal concen-
tration of serum lipoproteins, apart from one minor
aspect. There was slight evidence of a greater percen-
tage of serum chylomicrons. The electrophoretic
analysis showed a normal distribution of serum lipo-
proteins both in active and inactive multiple sclerosis.
Although these protein-lipid complexes have different
immunochemical characteristics, they did not change
quantitatively, even if brain antigens are released
during clinical exacerbation.
The subject of the present study did not include serum
fatty acids bound to albumin. Hypoalbuminemic states
in multiple sclerosis and decreased capacity of serum
albumin to bind congo red suggest that the transport
of some fatty acids may be modified. BAKER and co-
workers (10) found the reduction of linoleic acid
(18:2), and TUNA and coworkers (20) gave a lower
value for palmitic acid (16:0). In the cholesterol esters
CUMINGS and coworkers (21) measured a decreased
content of palmitic and stearic acid (18:0). This ab-
normality might be due either to a high level of oleic
acid (18:1) in the diet, which is known as a suppressing
factor in hepatic synthesis of linoleic acid, or to a
failure in intestinal absorption. Both hypotheses seem
to be .unlikely.
The serum level of cholesterol esters in patients with
clinical exacerbation was slightly lower than in other
groups of patients, but this difference was not signi-
ficant. BAKER and coworkers (11) found that the re-
duction of serum cholesterol esters and especially
cholesterol linoleate was correlated with the extent
and degree of recent clinical deterioration. No satis-
factory explanation of this abnormality is yet in sight,
but it may be suggested that immunologically active,
toxic factors diminish the activity of serum fatty acid
transferase, which is involved in the formation of
cholesterol esters.
The concentration of free cholesterol in the serum was
not altered, although a high standard deviation (^ 34,6
mg/100m/) and greater ranges of values (3—115mg/
100 m/) are worthy of note. GREEN and coworkers (1)
found a lack of correlation between the levels of total
cholesterol and y-globulin in the cerebrospinal fluid
from one side, and so did LIENHARDT (8) between
serum total cholesterol and the titre of anti-brain anti-
bodies from another. These observations weaken
markedly the supposition that cholesterol fluctuations
in multiple sclerosis are due to immunological me-
chanisms.
The analysis of serum lipids and proteins in patients
prior to and after treatment with corticotrophin or
hydrocortisone derivatives did not alter significantly
any of the studied constituents in multiple sclerosis.
Addendum
Studies of EPERJESSY and coworkers (Symp. on the Pa-
thology of Human Allergic Dis., Tirgu-Mures, 1967)
showed the possibility that protein portion of serum
lipoproteins in multiple sclerosis contains 19 amino
acids instead of 14 in normal controls. BOLTON and co-
workers (Lancet London, 1968/1, 99) found that low-
density lipoproteins include qualitatively altered phos-
pholipid, wich may cause increased plateled stickness
in multiple sclerosis.
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